Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1928P - Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): A prospective, open-label, phase II study

Date

14 Sep 2024

Session

Poster session 18

Topics

Clinical Research;  Immunotherapy

Tumour Site

Thyroid Cancer

Presenters

Jun Cao

Citation

Annals of Oncology (2024) 35 (suppl_2): S1122-S1128. 10.1016/annonc/annonc1614

Authors

J. Cao1, Q. ji2, M. Fang1

Author affiliations

  • 1 Key Laboratory Of Head & Neck Cancer Translational Research Of Zhejiang Province, Department Of Head And Neck And Rare Oncology, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 2 Department Of Head And Neck And Rare Oncology, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, 310022 - Hangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1928P

Background

PDTC/ATC are rare subtype cancers of thyroid cancer with a poor prognosis. Immune-checkpoint inhibitor (ICI) combined with antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment. We report the activity and safety of camrelizumab plus apatinib mesylate in patients with recurrent or metastatic PDTC/ATC.

Methods

In this single-center, open-label, single-arm, phase II trial, we enrolled participants (≥18 years) with recurrent or metastatic PDTC/ATC who were treatment-naive to ICI, regardless of PD-ligand 1 (PD-L1) expression and BRAF gene mutation. Patients received camrelizumab 200 mg every 3 weeks and apatinib 250 mg once per day or 1-5 days every week. The primary end point was objective response rate (ORR) and disease control rate (DCR) assessed by independent radiologists per RECIST version 1.1.

Results

21 patients were enrolled from April 9, 2020 to October 26, 2023. The median age was 61.0 years (range, 47-81). 14 patients were males (66.7%) and 7 females (33.3%). The Eastern Cooperative Oncology Group performance status score was 0 in 6 patients (28.6%), 1 in 10 patients (47.6%). and 2 in 5 patients (23.8%). The pathological diagnosis was PDTC in 12 patients (57.1%), ATC in 6 patients (28.6%), and mixed subtype thyroid cancer (MSTC) involved PDTC and ATC in 3 patients (14.3%). 15 patients underwent efficacy evaluation, including 8 partial response, 1 stable disease, and 6 progression disease. The objective response rate was 53.3%, and the disease control rate was 60%. The most common adverse events were grade 1-2. No patients experienced grade 4 adverse events.

Conclusions

Camrelizumab combined with apatinib mesylate had promising antitumor activity and manageable toxicities in recurrent or metastatic PDTC/ATC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.